EFFECT OF RADIATION AND CHEMOTHERAPY ON THE INTERFERON SYSTEM IN PATIENTS WITH NEOPLASTIC DISEASES (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

EFFECT OF RADIATION AND CHEMOTHERAPY ON THE INTERFERON SYSTEM IN PATIENTS WITH NEOPLASTIC DISEASES (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A210 1991. Unique Identifier : AIDSLINE ICDB/91671666
Ambrus J L; Chadha K; Stadler S; Halpern J; Khalil M; Piver S Hreschchyshyn MM; Ambrus CM; Roswell Park Cancer Inst., Buffalo, NY

Abstract: In patients with cancer of the gastrointestinal tract, pancreas, uterus, cervix, AIDS-related and -unrelated Kaposi's sarcoma and lymphoma, measurable interferon levels were present in the circulation. The Sendai virus-stimulated white cells had decreased alpha interferon-producing activity. Non-antibody type interferon inhibitory activity was found in the plasma. In normal controls, measurable interferon or interferon inhibitor activity was never found in the circulation. Interferon-producing activity in normal individuals was high or low. This characteristic remained constant over a 3-yr observation period. The question arises whether individuals in the normal control group who are low producers are at higher risk of carcinogenesis and viral infections because of impaired immunosurveillance than high producers. Impairment of the interferon system in cancer patients may contribute to infectious complications. Preliminary results indicate that interferon production is cAMP-related. cAMP-increasing agents (eg, pentoxifylline) increased interferon synthesizing activity of low producer white cells in vitro. Surgical-chemotherapy and/or radiation therapy induced remission of neoplastic disease resulted in normalization of the interferon system.

Keywords: Antineoplastic Agents/*ADVERSE EFFECTS Cyclic AMP/PHYSIOLOGY Disease Susceptibility Female Human Interferons/ANTAGONISTS & INHIB/*BLOOD Male Neoplasms/DRUG THERAPY/*ETIOLOGY/RADIOTHERAPY/*THERAPY Pentoxifylline/PHARMACOLOGY Radiotherapy/*ADVERSE EFFECTS Reference Values Risk Factors Virus Diseases/ETIOLOGY ABSTRACT
911030
M91A1117

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .